Small Cell Lung Cancer

Expansion of Ki67+ and ICOS+ (p=0.0024; 0.0074) CD8+ T cells was also observed in CD8+ T cells from long survivors exclusively from cohort 2. This study provides one of the few longitudinal assessments of peripheral immune dynamics in SCLC patients receiving ICBt, suggesting that early on-treatment changes, evaluated relative to each patient's own baseline levels, may provide greater predictive value than single-timepoint inter-patient comparisons.

Moving beyond immune checkpoint inhibitors (ICI), targeting DLL3 with tarlatamab in previously treated ES-SCLC generated an unprecedented response...Due to tumor heterogeneity and plasticity, rational combinations pursuing broader cancer cell vulnerabilities are likely necessary in the future to prevent relapse. Better tools for response monitoring are urgently needed to gauge progress.

Transcriptomics analyses were performed to investigate the effect of the deletion of the ArpA-like gene sclM4 on the expression of the scl biosynthetic genes, shedding light on the role of the corresponding transcriptional repressor. The present work improves understanding of scleric acid biosynthesis and provides new insights into the ArpA-like mediated regulation of biosynthetic gene expression in Streptomyces bacteria.

Absence of tumor response to oncologic treatment was strongly associated with higher mortality (88.9%) and final visual acuity worse than or equal to 20/200 (71.4%), whereas escalation of immunosuppression, such as immunoglobulin, plasmapheresis, and cyclophosphamide, was not associated with improved outcomes. Further investigation into the mechanisms by which CD8+ cytotoxic T-cell recruitment and activation in the pre-laminar optic nerve is essential to develop targeted therapies that can improve visual outcomes.

Patients with advanced LC exhibit elevated CCL2 and CCR2 levels in pleural effusions. Combined detection of these two markers has some diagnostic value in distinguishing between LUAD and LUSC, serving as a valuable supplement to histopathological examination; however, clinical application should involve a comprehensive assessment in conjunction with other auxiliary tests. These markers have limited value in distinguishing between SCLC and NSCLC.

High CD68+ macrophage infiltration is an independent favorable prognostic factor in surgically resected SCLC. Transcriptomic and deconvolution analyses suggest that the CD68-defined immune heterogeneity is consistent with M1-like macrophage enrichment, although this inference is based on computational deconvolution. Preliminary IHC validation with CD163, CD3, and CD8 on a subset of 83 cases confirmed globally enhanced immune infiltration in CD68-high tumors. A CD68-integrated prognostic nomogram was constructed for surgically resected SCLC patients.

P2, N=104, Active, not recruiting, National Cancer Institute (NCI) | Trial completion date: Jun 2026 --> May 2027

P3, N=660, Active, not recruiting, Hoffmann-La Roche | Trial completion date: Aug 2026 --> Feb 2028

In addition, in silico ADMET predictions were carried out to assess the developability profile of the lead candidates. The integrated chemical synthesis, biological evaluation, and computational modeling provided key insights into the reactivity, bioactivity, and structure-activity relationships of the synthesized compounds.

Reverse transcription-quantitative polymerase chain reaction (RT-qPCR) validation confirmed that the expression patterns of these candidate molecules were consistent with the RNA-Seq results. Three potential candidate molecules associated with TB were ultimately identified, although their disease specificity remains to be determined.

Early monitoring and prompt supportive management during initial treatment cycles are essential. These findings broaden current knowledge of tarlatamab safety in real-world practice and support prospective studies to pharmacovigilance-based signal stratification and monitoring strategies.

Durvalumab plus etoposide-platinum demonstrated a modest treatment response in neuroendocrine-transformed EGFR-mutated NSCLC. AEs were concordant with the known safety profiles of the combination, and no new safety signals were observed.